Evidence map›Paper›PMID 39465123›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024

Mechanism of Yi-Qi-Bu-Shen Recipe for the Treatment of Diabetic Nephropathy Complicated with Cognitive Dysfunction Based on Network Pharmacology and Experimental Validation.

Wenyi Li, Zhenguo Liu, Min Song, Zhenpeng Shi, Jihang Zhang, Junyu Zhou, Yidan Liu, Yun Qiao, Deshan Liu

Abstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Be Alert to Diabetes Nephropathy with Cognitive Dysfunction [Letter].Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  3. Be Alert to Diabetes Nephropathy with Cognitive Dysfunction [Response to Letter].Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenyi LiFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Zhenguo LiuFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Min SongFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Zhenpeng ShiFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Jihang ZhangTraditional Chinese Medicine College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Junyu ZhouFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Yidan LiuFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Yun QiaoDepartment of Traditional Chinese Medicine, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Deshan LiuDepartment of Traditional Chinese Medicine, Qilu Hospital of Shandong University, Jinan, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Diabetic nephropathy (DN) and cognitive dysfunction (CD) are common complications of diabetes. Yi-Qi-Bu-Shen Recipe (YQBS) can effectively reduce blood glucose, improve insulin resistance, and delay the progression of diabetic complications. The underlying mechanisms of its effects need to be further studied. Objective: This study elucidates the mechanism of YQBS in DN with CD through network pharmacology and experimental validation. Materials and Methods: Protein-protein interaction, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. Male Sprague-Dawley (SD) rats were divided into 6 groups: model, YQBS (2, 4, 8 g/kg), positive control (metformin, 200 mg/kg), and control; the DN model was established by high sugar and high fat diet combined with intraperitoneal streptozotocin injection. After the DN model was established, the rats were gavaged for 10 weeks. Serum, kidneys, and hippocampus tissues were collected to measure the expression levels of TLR4, NF-κB, TNF-α, and IL-6. Results: The network pharmacology analysis showed that quercetin and kaempferol were the main active components of YQBS. TNF and IL-6 were the key targets, and TLR4/NF-κB pathway was crucial to YQBS in treating DN complicated with CD. Experimental validation showed that the intervention of YQBS can reduce TNF-α and IL-6 in serum, and also significantly decreases the protein expression of TLR4 and NF-κB. Conclusion: YQBS exerts anti-inflammatory effects on DN with CD through TLR4/NF-κB pathway. This study provides a biological basis for the scientific usage of YQBS in inflammation diseases and supplies experimental evidence for future traditional Chinese medicine development.

Indexed as

cognitive dysfunctiondiabetes nephropathyinflammationnetwork pharmacologyYiqi Bushen Recipe

Identifiers

PMID39465123
PMCPMC11512782

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.